🧵 “Axial Spondyloarthritis: 10 Updated Guideline Pearls (ASAS–EULAR...

Treatment keeps evolving—here are the most important evidence-based recommendations 👇
#Rheumatology #MedTwitter #ClinicalPearls #Spondyloarthritis @IhabFathiSulima
✅ Chronic back pain >3 months, age <45.
✅ MRI sacroiliitis or HLA-B27 positivity confirms early disease.
🎯 Early diagnosis improves long-term function and prevents damage.
✅ Full-dose NSAIDs recommended either continuously or on demand.
✅ Strongest effect on pain and stiffness.
✅ Supervised physiotherapy is strongly recommended for all patients.
✅ Regular exercise improves mobility and quality of life.
✅ High disease activity despite NSAIDs?
✅ TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab) are preferred first biologics.
✅ Secukinumab, ixekizumab effective and approved.
✅ Avoid IL-17 inhibitors in active inflammatory bowel disease.
✅ Upadacitinib approved for active AS after biologic failure or intolerance.
✅ Careful VTE and cardiovascular risk assessment required.
✅ Methotrexate and sulfasalazine have no role for axial symptoms.
✅ Sulfasalazine may help peripheral arthritis.
✅ Uveitis or IBD:
🎯 Prefer monoclonal TNF inhibitors (adalimumab, infliximab, golimumab).
✅ Avoid etanercept.
✅ Target: Low disease activity (BASDAI <4) or remission.
✅ Reassess every 3–6 months.
✅ Switch within or across classes if:
•Inadequate response after 12–16 weeks
•Secondary loss of response
•Intolerance or side effects
Axial spondyloarthritis requires early diagnosis, structured exercise, and tailored biologic therapy.
✅ Follow these updated recommendations—outcomes are better when treatment is targeted.
🩺 Follow @Rheumat_Aravind for clear, practical autoimmune insights.
#Spondyloarthritis #Rheumatology #Autoimmune #MedEd #ClinicalPearls #MedTwitter